DadFinStart your free week
DadFin › Stocks › Consumer Defensive › KMB

Kimberly-Clark Corporation (KMB) stock score

Consumer Defensive · Household & Personal Products · United States

$97.59 ▼ -0.15% today

21.9
Dad Score, out of 100
weak

Kimberly-Clark Corporation (KMB) is a Household & Personal Products company in the Consumer Defensive sector, listed in the United States. On DadFin's weekly run it scores 21.9 out of 100 on the Dad Score, a weak reading that places the business ahead of 22% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Consumer Defensive it ranks #175 of 232. Its strongest axes are quality and liquidity; its weakest are growth and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Above average
Growth
Below average
Price action
Weak
Risk
Weak
Conviction
Below average
Liquidity
Strong
Macro
Weak

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)18.6×
P/E (forward)12.6×
Dividend yield5.38%
Return on capital28.8%
Operating margin19.0%
Revenue growth (YoY)-2.1%
FCF yield4.3%
Net debt / EBITDA1.60×
Piotroski F-Score5 / 9
52-week change-17.7%
Market cap$31.3B
Next earningsNov 3, 2026

What subscribers see on KMB

Start your free weekSubscriber? Open the full research →

Household & Personal Products peers

StockCompanyDad ScoreBandMarket cap
PGThe Procter & Gamble Company46.1middling$336.8B
ULUnilever PLC34.5weak$128.6B
CLColgate-Palmolive Company26.7weak$67.2B
ELThe Estée Lauder Companies Inc.53.8middling$33.3B
KVUEKenvue Inc.53.1middling$33.0B
CHDChurch & Dwight Co., Inc.59.6middling$22.4B
CLXThe Clorox Company8.9poor$9.7B
ELFe.l.f. Beauty, Inc.58.6middling$6.2B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.